About this trial

The aim of the present study is the identification, in liquid biopsies, of a new molecular panel able to discriminate renal cancer patients from controls, to discriminate patients with a malignant lesion from those with a benign mass, to determine aggressiveness of RCC, and to differentiate the most common histological subtypes of RCC (clear cell, papillary 1, papillary 2, and chromophobe).

This new molecular panel will be combined with clinical parameters to provide a screening test and to improve the accuracy and specificity of diagnosis, prognosis, and histological classification of renal cancer.

Eligibility criteria

Qualifiers

Men and women over 18 years of age

Diagnosis of first episode of renal mass

Caucasian race

Signed, informed consent

Disqualifiers

Any other concomitant cancer or history of active cancer in the last 5 years

Oncological genetic syndrome

Previous history of renal tumour

Urothelial cancer

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

1,000 Participants
are grouped into 2 trial groups

Locations

4
Italy
Azienda Ospedaliera Universitaria Careggi50139, Florence Italy
IRCCS San Raffaele20132, Milan Italy
Azienda Ospedaliera Universitaria San Luigi Gonzaga10043, Orbassano Italy
Spain
Fundació Puigvert08025, Barcelona Spain

Sponsors and collaborators

Biorek S.R.L.

Lead sponsor